title: A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
abstract: Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered: Research investigating the cost-effectiveness of vedolizumab is limited. This review considers data from the manufacturers, the evidence research group commissioned by NICE to conduct a single technology appraisal, and the decision of NICE itself to appraise what is currently known about the cost-effectiveness of vedolizumab for moderately to severely active ulcerative from a UK perspective. Expert commentary: Based on the very limited data currently available, it can be concluded that vedolizumab is a cost-effective option for those with moderately to severely active ulcerative colitis who are anti-TNFa naive; however, there is a need for further research comparing vedolizumab with other biologic therapies which may alter perceptions of cost-effectiveness.
authors.affiliation: a Inflammatory Bowel Diseases Unit, Department of Gastroenterology , Castle Hill Hospital , Cottingham , UK.
authors.forename: Her Hsin
authors.initials: HH
authors.lastname: Tsai
authors.affiliation: a Inflammatory Bowel Diseases Unit, Department of Gastroenterology , Castle Hill Hospital , Cottingham , UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: Black
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D003362:Cost-Benefit Analysis; D005765:Gastrointestinal Agents / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D006113:United Kingdom
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D016023:Integrins; C071777:integrin alpha4beta7; C543529:vedolizumab
keywords: Vedolizumab; cost-effectiveness; inflammatory bowel disease; ulcerative colitis